Gold bars to be exempt from tariffs, White House clarifies
REDWOOD CITY, CA—Kavita Patel, a director at Arcellx , Inc. (NASDAQ:ACLX), a $3.7 billion market cap biotechnology company, recently executed a notable transaction involving the company’s common stock. On June 10, 2025, Patel sold 1,500 shares at $67.36 per share, totaling approximately $101,040. According to InvestingPro analysis, the stock is currently trading above its Fair Value. This transaction was conducted under a pre-established Rule 10b5-1 trading plan, which Patel entered on March 28, 2024.
On the same day, Patel also exercised stock options to acquire 1,500 shares at a price of $6.66 per share. Following these transactions, Patel holds no shares from the sale but retains a total of 27,077 shares through direct ownership. The options exercised were part of Arcellx’s 2017 Equity Incentive Plan, with vesting conditions tied to Patel’s continued service to the company. InvestingPro data shows strong analyst support with a consensus "Strong Buy" rating and price targets ranging from $93 to $134.
These transactions highlight Patel’s strategic management of her holdings in Arcellx, reflecting her ongoing participation in the company’s equity plans. For deeper insights into ACLX’s valuation and growth prospects, including 13 additional ProTips and comprehensive financial analysis, check out the detailed Pro Research Report available on InvestingPro.
In other recent news, Arcellx, Inc. has announced the appointment of Andrew Galligan and Kristin Myers to its Board of Directors as the company prepares for the anticipated commercial launch of its lead product candidate, anito-cel, in 2026. Galligan, with over thirty years of financial leadership experience, and Myers, with two decades in the healthcare industry, are expected to strengthen Arcellx’s commercial strategies and operations. Their appointments follow Arcellx’s business progress in 2024 and aim to bolster the company’s financial infrastructure and healthcare sector leadership. The company is focused on developing cell therapies for cancer and other incurable diseases, with anito-cel targeting the treatment of multiple myeloma. Arcellx’s forward-looking statements emphasize their belief in anito-cel’s potential to benefit patients with relapsed or refractory multiple myeloma. However, these statements involve assumptions that may not materialize and are subject to risks and uncertainties. The company’s progress towards the commercial launch of anito-cel is in partnership with Kite, a Gilead (NASDAQ:GILD) Company, and is contingent upon regulatory approval.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.